Doxepin Dosing for Insomnia
For adults with chronic insomnia, use low-dose doxepin 3 mg or 6 mg taken once nightly at bedtime, specifically for sleep maintenance insomnia (difficulty staying asleep). 1, 2
Recommended Dosing by Age
Adults (18-64 years)
- Standard dose: 3 mg or 6 mg once nightly at bedtime 1
- Both doses demonstrate clinically significant improvements in wake after sleep onset (WASO), total sleep time (TST), and sleep efficiency 1
- The 6 mg dose shows slightly greater efficacy for sleep maintenance but comparable safety profile 1
Elderly Adults (≥65 years)
- Start with 3 mg once nightly at bedtime 2, 3
- May increase to 6 mg if needed and tolerated
- Elderly patients require lower starting doses due to increased risk of confusion and oversedation 3
- Both 3 mg and 6 mg doses are effective and well-tolerated in elderly populations 4
Key Clinical Considerations
Indication Specificity
Doxepin is specifically indicated for sleep maintenance insomnia, NOT sleep onset insomnia. 1 The drug demonstrates:
- Significant reduction in WASO: 22-23 minutes greater than placebo 1
- Increased TST: 26-32 minutes longer than placebo 1
- Improved sleep efficiency throughout the night, including the final third 1, 4
- Minimal effect on sleep latency (falling asleep initially) 1
Duration of Treatment
The 2020 VA/DoD guidelines recommend a short course of low-dose doxepin for patients unable or unwilling to receive cognitive behavioral therapy for insomnia (CBT-I) 2. However, studies demonstrate sustained efficacy for:
- Up to 5 weeks with no tolerance development 5
- Up to 12 weeks with maintained symptom control 6
- No evidence of rebound insomnia upon discontinuation 5, 6
Administration Guidelines
- Take on an empty stomach to maximize effectiveness 7
- Administer 30 minutes before bedtime
- Maximum recommended dose: 6 mg for insomnia (note: higher doses of 25-300 mg are used for depression, NOT insomnia) 7, 1
Safety Profile
Advantages Over Other Hypnotics
Low-dose doxepin has a favorable safety profile compared to benzodiazepines and nonbenzodiazepine receptor agonists:
- No next-day residual sedation at 3 mg or 6 mg doses 1, 5, 4, 8
- No anticholinergic effects reported at low doses 5, 4, 8
- No memory impairment 4, 8
- No rebound insomnia after discontinuation 5, 6
- No evidence of physical dependence 6
- Preserved sleep architecture 8
Common Adverse Effects
The most frequently reported side effects are:
- Somnolence (mild increase at 6 mg) 1
- Headache 1
- Diarrhea (at 3 mg) 1
- Upper respiratory infection (at 3 mg) 1
Adverse event rates are generally comparable to placebo, though incidence may increase with longer treatment duration 2
Important Warnings
- Suicide risk: While low-dose doxepin has no black box warning for suicide, the risk for suicidal ideation cannot be excluded 2
- Elderly patients: Start at low doses due to risk of confusion and oversedation 3
- Contraindications: Not recommended during pregnancy or nursing 7
- Use caution in patients with depression, respiratory compromise (asthma, COPD, sleep apnea), or hepatic/cardiac disease 7
Clinical Context and Alternatives
First-Line Treatment
Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment for chronic insomnia, with superior long-term outcomes compared to all pharmacologic therapies 2. Doxepin should be reserved for patients who:
- Cannot access CBT-I
- Are unwilling to pursue CBT-I
- Need short-term symptom relief while awaiting behavioral therapy
Comparison to Other Medications
The 2017 American Academy of Sleep Medicine guidelines give doxepin a WEAK recommendation (as with all insomnia medications), but it is specifically recommended for sleep maintenance rather than sleep onset 1. For sleep onset insomnia, consider:
Avoid trazodone for insomnia treatment, as guidelines recommend against its use due to insufficient evidence and potential harms outweighing benefits 2, 1, 2, 1
Mechanism of Action
Low-dose doxepin works through selective histamine H1 receptor antagonism at 3-6 mg doses, which promotes sleep maintenance without the anticholinergic, alpha-adrenergic, or serotonergic effects seen at higher antidepressant doses 6, 4.